Innovo Therapeutics Inc.

Company Profile

Innovation toward conquering human diseases
I’m pleased to introduce our company to you eventually.

Innovo Therapeutics is a biotech company established by multiple experts with more than 20 years of experience in new drug development, focusing on NCE (new chemical entity) discovery.

Our goal is to develop new drugs for patients suffering from intractable diseases such as idiopathic pulmonary fibrosis, osteoarthritis, ulcerative colitis, etc.

Our primary research field is fibrosis, inflammation, immunology and oncology.

Innovo has developed DeepZema®, an AI-augmented drug development platform, with all our efforts because we acknowledge how critical minimizing errors and increasing success rates in the new drug development process is. In addition, the expertise of the research faculty leads to the acceleration of R&D projects.

Our fundamental objective of starting a new company was centered around caring for patients. This will never change. We always do our best to make our development outcomes ready for patients in the market as fast as possible.

We, employees of Innovo Therapeutics, want to share our promise to be the leading bio-company shortly, keeping a high level of our contribution to human health & life.

Thank you,

Company History

January, 2024 Received a DIPS** 1000+ grant ** Deep-Tech Incubator Project for Startups
August, 2024 Succeeded in Phase 2 clinical trial of INV-001 by MFDS* (Scar treatment) * Ministry of Food and Drug Safety
June, 2023 Received a KDDF grant (INV-008)
September, 2023 Certified as a Company of Excellence in Employee Invention Promotion (2023.09 ~2025.09)
October, 2023 Received a KDDF*** grant (INV-004, preclinical) *** Korea Drug Development Fund
July, 2023 Received a National Center for Cosmetics R&D grant (INC-001)
April, 2023 Received a DIPS 1000+ grant
September, 2022 Received a KDDF grant (INV-101, phase 1)
November, 2022 Approved phase 2 IND by MFDS (Scar treatment)
March, 2022 Approved phase 1 IND by US FDA (Ulcerative Colitis)
October, 2021 Received a KDDF grant (INV-101, pre-clinical)
September, 2021 Received a KDDF grant (INV-005)
June, 2021 Headquarter relocated (Mapo-gu, Seoul, Republic of Korea)
November, 2021 Completed Series B funding
September, 2020 Received an Innovative Sector Startup Package (BIG3) grant
January, 2020 R&D center established (Youseong-gu, Daejeon, Republic of Korea)
December, 2020 Received a Ministry of SMEs and Startups grant (INV-006)
December, 2019 Completed Series A funding
June, 2019 In-Licensing of IBD
March, 2019 Incorporated

Factory / Branch Office

Innovo Therapeutics Inc. (https://innovothera.com/en/)

  • The person in charge

    Park Heedong
  • Telephone

    82-0269568680
  • Fax

    -
  • Address

    38 Mapo-daero, Mapo-gu, Seoul (04174)
Business Type Other
Main Product Motifull® hair tonic 15ml, Motifull® hair tonic 50ml , Motifull® hair shampoo , Motifull® hair shamp
Established 2019-03-18
Total Annual Revenue
Total Employees 11~50 people